Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa.
Pharmaceutical Chemistry, School of Pharmacy, North-West University, Potchefstroom, South Africa.
Chem Biol Drug Des. 2022 Mar;99(3):416-437. doi: 10.1111/cbdd.13999. Epub 2021 Dec 27.
Over the past few years, great progress has been made in the development of high-affinity adenosine A and/or A receptor antagonists-promising agents for the potential treatment of Parkinson's disease. Unfortunately, many of these compounds raise structure-related concerns. The present study investigated the effect of ring closures on the rA /A affinity of compounds containing a highly reactive α,β-unsaturated carbonyl system, hence providing insight into the potential of heterocycles to address these concerns. A total of 12 heterocyclic compounds were synthesised and evaluated in silico and in vitro. The test compounds performed well upon qualitative assessment of drug-likeness and were generally found to be free from potentially problematic fragments. Most also showed low/weak cytotoxicity. Results from radioligand binding experiments confirm that heterocycles (particularly 2-substituted 3-cyanopyridines) can replace the promiscuous α,β-unsaturated ketone functional group without compromising A /A affinity. Structure-activity relationships highlighted the importance of hydrogen bonds in binding to the receptors of interest. Compounds 3c (rA K = 16 nM; rA K = 65 nM) and 8a (rA K = 102 nM; rA K = 37 nM), which both act as A antagonists, showed significant dual A /A affinity and may, therefore, inspire further investigation into heterocycles as potentially safe and potent adenosine receptor antagonists.
在过去的几年中,在开发高亲和力的腺苷 A 和/或 A 受体拮抗剂方面取得了巨大进展,这些拮抗剂是治疗帕金森病的潜在药物。不幸的是,许多这些化合物都存在与结构相关的问题。本研究调查了环化对含有高反应性α,β-不饱和羰基系统的化合物对 rA/A 亲和力的影响,从而深入了解杂环化合物解决这些问题的潜力。总共合成了 12 种杂环化合物,并进行了计算机模拟和体外评估。测试化合物在药物相似性的定性评估中表现良好,通常不存在潜在问题的片段。大多数化合物还表现出低/弱的细胞毒性。放射性配体结合实验的结果证实,杂环(特别是 2-取代的 3-氰基吡啶)可以替代混杂的α,β-不饱和酮官能团,而不会影响 A/A 亲和力。构效关系强调了氢键在与受体结合中的重要性。化合物 3c(rA K = 16 nM;rA K = 65 nM)和 8a(rA K = 102 nM;rA K = 37 nM)均为 A 拮抗剂,表现出显著的双重 A/A 亲和力,因此可能激发对杂环作为潜在安全有效腺苷受体拮抗剂的进一步研究。